Top High Growth Tech Stocks To Watch In Australia October 2024

In This Article:

Over the last 7 days, the Australian market has risen 1.7%, with notable movements in sectors such as Materials, which is up 12%, and Financials, which is down 3.2%. In this environment of overall growth and positive earnings forecasts, identifying high growth tech stocks can be crucial for investors looking to capitalize on robust market conditions.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Adherium

86.80%

73.66%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

Telix Pharmaceuticals

20.10%

38.31%

★★★★★★

DUG Technology

10.79%

31.83%

★★★★★☆

AVA Risk Group

32.56%

118.83%

★★★★★★

Pointerra

56.62%

126.45%

★★★★★★

Careteq

37.17%

126.21%

★★★★★☆

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland with a market cap of A$1.38 billion.

Operations: The company generates revenue primarily through the development of its cell technology platform for commercialization, amounting to $5.90 million. With a market cap of A$1.38 billion, Mesoblast focuses on advancing regenerative medicine products across multiple international markets.

Mesoblast, navigating a challenging landscape in biotechnology, reported a revenue decline to $5.9 million from $7.5 million year-over-year and an increased net loss of $87.96 million, up from $81.89 million. Despite these financial setbacks, the company is poised for significant advancements with its lead product candidate Ryoncil (remestemcel-L), targeting pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). The U.S. FDA's acceptance of their Biologics License Application resubmission reflects potential market breakthroughs with projected revenue growth at 45.8% annually—outpacing the Australian market's 5.5%. Moreover, Mesoblast’s strategic focus on high-stakes regulatory approvals could transform its financial trajectory as it anticipates profitability within three years amidst a forecasted earnings surge of 60.82% per year.

ASX:MSB Earnings and Revenue Growth as at Oct 2024
ASX:MSB Earnings and Revenue Growth as at Oct 2024

REA Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: REA Group Limited, along with its subsidiaries, operates an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam and other international markets and has a market cap of A$27.83 billion.